Drug Development

Pfizer Invests In Nodality; SOCMA Approves New Members; And More.

Merck Ends Partnership With Dynavax; PhRMA Elects Officers; And More.

Abbott Agrees to Acquire Facet Biotech; FDA Issues Black-Box Warning For Plavix; and More.

Continuous manufacturing could bring the pharmaceutical industry advantages such as improved product quality, easy scale-up, flexibility, and short cycle times. But how can a company switch from batch to continuous manufacturing?

Exelixis And XenoPort Announce Job Cuts; GSK Dedicates India Facility; And More.

Astellas Pharma Makes Bid for OSI Pharmaceuticals; Ringo Retiring From Pfizer; And More.

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

Pre-Interphex 2010 Product Releases.

To best carry out the vision of Hatch-Waxman, Congress must act now on biogenerics.

Brief pharmaceutical news items for March 2010.

Analysis of the opportunities and challenges in the biosimilars market.

From last-minute product inserts to putting out fires, close calls are a common occurrence.

It's time to maintain a thorough traceable excipient trail.

If both sides of the aisle don't agree on even mild healthcare reform soon, the bill could die out.

The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.

Pharmaceutical Technology talked to drugmakers, equipment vendors, and service providers to learn more about the advantages and disadvantages of rapid microbial-detection methods.

Merck To Eliminate 15,000 jobs; Tauzin Stepping Down At PhRMA; And More.

RUSNANO, a corporation established by the Russian government to foster the development of nanotechnology, launched a project last week to manufacture targeted-delivery nanodrugs to treat malignant neoplasms.

Abbott Completes Acquisition Of Solvay; Merck Names President of Consumer Healthcare; And More.

VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.

Capsules that can release their contents at a selected temperature have been developed by researchers in France, and could lead to the development of therapeutic agents that are applied to the skin and triggered locally by rubbing.

Cephalon Buys Mepha; BASi's CEO Retires; and More.

Hoping to prevent the deaths of eight million children over the next decade, Bill and Melinda Gates recently committed $10 billion for child-immunization programs in the world's poorest countries.

The author discusses how the use of a visible residue limit has made the 10-ppm cleaning limit obsolete in many applications.

Sharing too much-or too little-information can have disastrous onsequences.